Data / Form D filings / Auspex Pharmaceuticals, Inc.
Auspex Pharmaceuticals, Inc.: Form D filings
Auspex Pharmaceuticals, Inc., a pharmaceuticals company in La Jolla, CA, filed 9 Form D notices with the SEC between 2009 and 2013. The latest, on September 6, 2013, reports $28 million sold of a $28 million offering to 9 investors.
Find out what Auspex Pharmaceuticals, Inc. does, who founded it and who invested, beyond what the filing says. $10 of credit on sign-up, no card.
SpecStream is the live web data engine for teams and agents. It reads every Form D on SEC EDGAR the day it is filed, and this page is that reading. Ask for your own cut (a state, an industry, a size) and new filings arrive in your sheet, CRM, Slack or agent as they land.
Company details from the filing
- Address
- 3366 N. TORREY PINES COURT, SUITE 225, La Jolla, CA, 92037
- Phone
- (858) 558-2400
- Industry
- Pharmaceuticals
- Entity type
- Corporation
- Incorporated in
- Delaware
- Revenue range
- Decline to Disclose
- Exemptions claimed
- Rule 506
- SEC identifier (CIK)
- 1454189
The full lists. Form D filings in California: 5,891 rows, $138.91, or the new rows each week for $19 a month. Form D filings in Pharmaceuticals: 346 rows, $17.30, or the new rows each week for $19 a month. Pay by card with no account. Prices exclude VAT. CSV and Excel files with the columns this page does not show (company, CIK, year incorporated, street, city, state and 5 more), which open on your screen as soon as the payment clears and come by email. For agents and scripts: every list with its row count and price is at https://specstream.ai/data/lists.json.
Form D filings
| Filed | Type | Offering | Sold | Remaining | Investors | First sale | Filing |
|---|---|---|---|---|---|---|---|
| Sep 6, 2013 | Amendment | $27,992,742 | $27,992,742 | $0 | 9 | Oct 31, 2012 | sec.gov |
| Nov 14, 2012 | New notice | $25,492,741 | $17,492,739 | $8,000,002 | 8 | Oct 31, 2012 | sec.gov |
| Jul 31, 2012 | New notice | $3,000,000 | $1,500,000 | $1,500,000 | 5 | Jul 18, 2012 | sec.gov |
| Jan 11, 2012 | New notice | $6,000,000 | $3,000,000 | $3,000,000 | 7 | Dec 15, 2011 | sec.gov |
| Jul 30, 2010 | New notice | $13,825,000 | $13,825,000 | $0 | 5 | Jun 15, 2007 | sec.gov |
| Jul 16, 2010 | New notice | $11,999,999 | $11,999,999 | $0 | 8 | Jul 2, 2010 | sec.gov |
| Feb 26, 2010 | New notice | $2,000,000 | $2,000,000 | $0 | 6 | Jan 8, 2010 | sec.gov |
| Oct 22, 2009 | New notice | $2,000,000 | $2,000,000 | $0 | 5 | Oct 9, 2009 | sec.gov |
| Aug 3, 2009 | New notice | $3,000,000 | $3,000,000 | $0 | 7 | May 22, 2009 | sec.gov |
Executive officers and directors named in the filing
| Name | Role | Note in the filing |
|---|---|---|
| Sep Sarshar | Director | |
| David. A. Stamler | Executive Officer | |
| Andreas Sommer | Executive Officer | |
| David Collier | Director | |
| Pratik A. Shah | Executive Officer, Director | |
| Rod A. Ferguson | Director | |
| Samuel Saks | Director |
Other pharmaceuticals companies in California that filed recently
- Anvion Bio, Inc. $100,000 · Oct 7, 2026
- Aqur Biosciences, Inc. $1.5 million · Sep 18, 2026
- BTB Therapeutics, Inc. $8.9 million · Aug 12, 2026
Every Form D from the week of Sep 2, 2013 · All recent filings in California · All recent Pharmaceuticals filings
Read from SEC EDGAR. Amount sold is what Auspex Pharmaceuticals, Inc. reported on the day it filed; on an offering that is still open, a later amendment can raise it. Free to reuse with credit to SpecStream under CC BY 4.0.
$10 of credit on sign-up, no card.